01 — At a Glance
The Formulation Juggernaut Nobody Invited to the Party
- 52-Week High / Low₹1,279 / ₹994
- Q3 Revenue₹8,646 Cr
- Q3 PAT₹910 Cr
- Q3 EPS₹15.67
- Annualised EPS (Q3×4)₹62.68
- Book Value₹603
- Price to Book2.04x
- Dividend Yield0.32%
- Debt / Equity0.22x
- ROCE14.2%
The Auditor Says: Aurobindo closed Q3 FY26 with ₹8,646 crore revenue (+8.4% YoY), ₹910 crore PAT, 20.5% EBITDA margin, and dropped a Pomalidomide generic launch in the US market on the same day the results came out. P/E ratio is 20.3x against sector median of 27.6x. Not overvalued by pharma standards. Not cheap either. Fair game. Europe revenue grew 27% YoY — that’s the story hiding in plain sight.
02 — Introduction
The Second-Largest Pharma Company That Never Wins Awards
Here’s a fun fact: Aurobindo Pharma is India’s second-largest listed pharmaceutical company by revenue. They make generics. Active pharmaceutical ingredients (APIs). Injectable formulations. And they’re one of the few Indian pharma companies that can build a penicillin plant from scratch and actually make it work profitably.
But they’re not the sexy stock in your portfolio. No COVID tailwinds. No biotech halo. No “India’s answer to Moderna” nonsense. Just 853 ANDA filings with the US FDA, presence in 150+ countries, manufacturing footprints in India, Portugal, Brazil, and the US, and a business model that quietly prints cash every quarter.
Q3 FY26 is when things get interesting. Europe is growing 27% YoY. APIs — the boring ingredient business — is scaling profitably. And the government just protected Indian antibiotic makers with a Minimum Import Price (MIP) policy that makes Aurobindo’s Pen-G strategy print money starting Q4 FY26. The concall transcripts from February 2026 tell a story of a company that’s about to enter a different growth phase. Let’s parse what’s actually happening.
Concall Note (Feb 2026): “Low double digit growth in Europe is well ahead of the market growth rate.” Management expects Europe to cross €1 billion in annual run-rate by the end of FY26. That’s a goal. That’s execution. That’s the trajectory of a ₹70k+ crore market-cap company pivoting regionally.
03 — Business Model: Who Are They?
Generics. Injectables. Antibiotics. And Pills That Save Lives.
Aurobindo’s business is split into two main buckets: Formulations (89% of revenues) and APIs (11%). Formulations are the finished pills, liquids, and injectables you pop. APIs are the active ingredients that big pharma companies buy to turn into their own pills.
On formulations: they operate in the US market (46% of total sales), Europe (27%), growth markets like Latin America and Africa (13%), and anti-retroviral treatments for HIV (4%). Their US business is dominated by generic oral solid dosages (68% of US sales) — think off-patent versions of blood pressure pills, antacids, and painkillers that insurance companies mandate. They also have a fast-growing injectable business (17% YoY growth in Q3) where they make sterile versions of Parkinson’s meds, eye injections, and hospital-grade formulations.
On APIs: they manufacture beta-lactams (penicillins, cephalosporins — 72% of API sales) and non-beta-lactams. Beta-lactams are commoditized globally. Prices are crushed. Competition is fierce. But Aurobindo has now built India’s first world-class Pen-G and 6-APA facility, thanks to government subsidies (PLI scheme). This facility was supposed to lose money for years. Instead, management says it’s already broken even and expecting ₹240 crore annual PLI incentive for every 10,000 MT of output. Tailwind incoming.
US46%of Revenue
Europe27%of Revenue
Growth Mkts13%of Revenue
ARV4%of Revenue
Manufacturing Sprawl: 29 manufacturing facilities across India, Portugal, Brazil, and the US. Formulation capacity: 50 billion units annually. API capacity: 19,000 metric tonnes per annum. Penicillin facility (first in 2024): 15,000 TPA. That’s scale. That’s complexity. That’s also regulatory exposure.
💬 Drop a comment: Does Aurobindo’s Pen-G strategy remind you of any other country’s self-reliance push? And is government protection of antibiotic pricing actually a good thing?
04 — Financials Overview
Q3 FY26: The Numbers Don’t Lie (They Just Confuse)
Result Type: QUARTERLY RESULTS | Q3 EPS: ₹15.67 | Annualised EPS (Q3×4): ₹62.68 | Full-year FY26 EPS (Guidance): TBD
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 8,646 | 7,979 | 8,286 | +8.4% | +4.3% |
| Operating Profit (EBITDA) | 1,773 | 1,578 | 1,678 | +12.3% | +5.7% |
| EBITDA Margin % | 20.5% | 19.8% | 20.2% | +70 bps | +30 bps |
| PAT | 910 | 846 | 848 | +7.6% | +7.3% |
| EPS (₹) | 15.67 | 14.56 | 14.61 | +7.6% | +7.3% |
The Margin Story: EBITDA margin expanded 70 basis points YoY to 20.5%. Management credits “softer raw material prices and business mix.” Translation: global commodity cycle is in Aurobindo’s favour right now. Gross margin hit 59.7% — best in the cycle. Q3 also had a one-time labour code cost of ₹65 crore that suppressed PAT. Strip that, and PAT growth would’ve been north of 15% YoY. But management stays conservative with accounting. Welcome the transparency.
05 — Valuation: Fair Value Range
Is ₹1,232 The Price or The Opportunity?
Join 10,000+ investors who read this every week.
